MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Clinical Trial ID NCT00094653

PubWeight™ 96.24‹?›

🔗 Visit the page for NCT00094653

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 67.34
2 Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015 5.49
3 Antibody-based therapeutics to watch in 2011. MAbs 2011 2.00
4 Antibodies to watch in 2010. MAbs 2010 1.90
5 Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013 1.65
6 Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013 1.23
7 Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 2013 1.15
8 Tumor evasion from T cell surveillance. J Biomed Biotechnol 2011 1.01
9 Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 2014 0.98
10 Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes 2012 0.92
11 Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014 0.89
12 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
13 Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res 2015 0.86
14 Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med 2013 0.85
15 Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab. Cancer Res 2015 0.85
16 Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 2016 0.84
17 Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology 2014 0.84
18 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
19 Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). Oncol Rep 2014 0.82
20 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
21 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
22 Ipilimumab. Drugs R D 2010 0.79
23 Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc 2015 0.78
24 Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? PLoS One 2015 0.78
25 The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. PLoS One 2015 0.78
26 Predictive factors for immunotherapy in melanoma. Ann Transl Med 2015 0.77
27 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
28 A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. J Immunother Cancer 2015 0.76
29 Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health Qual Life Outcomes 2014 0.76
30 Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther 2014 0.75
31 The role of checkpoints in the treatment of GBM. J Neurooncol 2015 0.75
32 Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother 2016 0.75
33 The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. Cancers (Basel) 2015 0.75
Next 100